Spots Global Cancer Trial Database for A Phase 1 Study of XL019 in Adults With Polycythemia Vera
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1 Study of XL019 in Adults With Polycythemia Vera
Official Title: A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera
Study ID: NCT00595829
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of the JAK2 inhibitor XL019 administered orally in adults with Polycythemia Vera.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA School of Medicine, Center for Health Sciences, Los Angeles, California, United States
UCSF - Division of Hematology/Oncology, San Francisco, California, United States
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
University of Michigan Health System, Ann Arbor, Michigan, United States
Weill Cornell Medical College, New York, New York, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
